Comparative Pharmacology
Head-to-head clinical analysis: DESOGEN versus MODICON 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOGEN versus MODICON 28.
DESOGEN vs MODICON 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces changes in cervical mucus and endometrium, impeding sperm penetration and implantation.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
One tablet orally once daily, each tablet containing 0.035 mg ethinyl estradiol and 0.4 mg norethindrone, taken at the same time each day for 21 days followed by 7 days of placebo tablets.
None Documented
None Documented
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Terminal elimination half-life: 13-19 hours (mean 16 hours) for norethindrone; steady state achieved within 5-7 days.
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Renal: 50-60% as metabolites, fecal: 40-50% as metabolites, with enterohepatic circulation; less than 1% unchanged in urine.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive